| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Aneurysm, Thoracic | 22 | 2021 | 134 | 6.160 |
Why?
|
| Aorta, Thoracic | 18 | 2021 | 211 | 4.400 |
Why?
|
| Marfan Syndrome | 7 | 2021 | 42 | 2.910 |
Why?
|
| Matrix Metalloproteinases | 9 | 2016 | 223 | 2.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2017 | 44 | 1.740 |
Why?
|
| MicroRNAs | 7 | 2021 | 447 | 1.440 |
Why?
|
| Matrix Metalloproteinase 14 | 6 | 2016 | 44 | 1.340 |
Why?
|
| Aortic Valve | 6 | 2017 | 249 | 1.290 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 384 | 1.260 |
Why?
|
| Loeys-Dietz Syndrome | 2 | 2021 | 10 | 1.210 |
Why?
|
| Fibroblasts | 10 | 2021 | 902 | 1.200 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 6 | 2016 | 85 | 1.130 |
Why?
|
| Heart Valve Diseases | 3 | 2017 | 123 | 1.040 |
Why?
|
| Disease Models, Animal | 16 | 2021 | 2550 | 0.990 |
Why?
|
| Vascular Remodeling | 3 | 2021 | 34 | 0.880 |
Why?
|
| Aorta | 4 | 2021 | 316 | 0.850 |
Why?
|
| Pyrazoles | 3 | 2017 | 190 | 0.800 |
Why?
|
| Pyrimidines | 3 | 2017 | 178 | 0.800 |
Why?
|
| Matrix Metalloproteinase 2 | 6 | 2017 | 145 | 0.790 |
Why?
|
| Aorta, Abdominal | 4 | 2017 | 97 | 0.780 |
Why?
|
| Signal Transduction | 8 | 2021 | 2689 | 0.740 |
Why?
|
| Cardiovascular System | 1 | 2021 | 85 | 0.710 |
Why?
|
| Matrix Metalloproteinase 9 | 6 | 2017 | 160 | 0.680 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 331 | 0.670 |
Why?
|
| Exome | 1 | 2019 | 20 | 0.650 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 1293 | 0.650 |
Why?
|
| Disease Progression | 11 | 2019 | 1038 | 0.650 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2017 | 64 | 0.600 |
Why?
|
| Gene Expression Regulation, Enzymologic | 6 | 2016 | 282 | 0.580 |
Why?
|
| Yoga | 1 | 2017 | 18 | 0.580 |
Why?
|
| Cathepsins | 1 | 2016 | 37 | 0.560 |
Why?
|
| Sulfonamides | 1 | 2017 | 141 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 468 | 0.540 |
Why?
|
| Animals | 30 | 2021 | 20881 | 0.540 |
Why?
|
| Arteries | 1 | 2016 | 108 | 0.520 |
Why?
|
| Enzyme Activation | 2 | 2016 | 791 | 0.510 |
Why?
|
| Pulmonary Artery | 2 | 2014 | 323 | 0.480 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 114 | 0.470 |
Why?
|
| Phosphatidic Acids | 2 | 2005 | 12 | 0.470 |
Why?
|
| Atherosclerosis | 1 | 2016 | 204 | 0.460 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 1070 | 0.460 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2005 | 67 | 0.450 |
Why?
|
| Humans | 40 | 2021 | 68618 | 0.440 |
Why?
|
| Arteriovenous Malformations | 1 | 2013 | 34 | 0.440 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 2791 | 0.440 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 710 | 0.430 |
Why?
|
| Mice | 17 | 2019 | 8474 | 0.430 |
Why?
|
| RNA, Messenger | 6 | 2019 | 1664 | 0.390 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 371 | 0.390 |
Why?
|
| Blood Pressure | 2 | 2016 | 1451 | 0.380 |
Why?
|
| Endothelial Cells | 1 | 2013 | 384 | 0.360 |
Why?
|
| Male | 27 | 2019 | 37321 | 0.360 |
Why?
|
| Microfilament Proteins | 2 | 2010 | 102 | 0.350 |
Why?
|
| Down-Regulation | 1 | 2011 | 447 | 0.350 |
Why?
|
| Female | 26 | 2019 | 38074 | 0.340 |
Why?
|
| Time Factors | 11 | 2017 | 4655 | 0.330 |
Why?
|
| Immunoblotting | 3 | 2019 | 254 | 0.320 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 596 | 0.320 |
Why?
|
| Extracellular Matrix | 4 | 2015 | 493 | 0.310 |
Why?
|
| Tricuspid Valve | 1 | 2007 | 42 | 0.300 |
Why?
|
| Hypertension | 1 | 2016 | 1535 | 0.290 |
Why?
|
| Piperidines | 4 | 2017 | 123 | 0.290 |
Why?
|
| Receptors, Transforming Growth Factor beta | 4 | 2014 | 56 | 0.290 |
Why?
|
| Aged | 12 | 2019 | 14862 | 0.280 |
Why?
|
| Fibrillin-1 | 2 | 2021 | 18 | 0.280 |
Why?
|
| Dilatation, Pathologic | 4 | 2021 | 58 | 0.280 |
Why?
|
| Mitral Valve | 1 | 2007 | 166 | 0.270 |
Why?
|
| Protein Kinase C | 1 | 2007 | 270 | 0.270 |
Why?
|
| Angiotensin II | 4 | 2017 | 220 | 0.270 |
Why?
|
| Middle Aged | 14 | 2019 | 21147 | 0.270 |
Why?
|
| Mutation | 5 | 2015 | 1213 | 0.260 |
Why?
|
| Genetic Therapy | 2 | 2021 | 291 | 0.260 |
Why?
|
| Myocardium | 4 | 2018 | 1204 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 626 | 0.250 |
Why?
|
| Swine | 4 | 2017 | 672 | 0.250 |
Why?
|
| Prognosis | 5 | 2019 | 2093 | 0.250 |
Why?
|
| Cells, Cultured | 5 | 2021 | 2673 | 0.250 |
Why?
|
| Heart Failure | 3 | 2020 | 1180 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 183 | 0.240 |
Why?
|
| Collagen | 4 | 2018 | 636 | 0.230 |
Why?
|
| Aortic Aneurysm, Abdominal | 3 | 2017 | 139 | 0.230 |
Why?
|
| Calcium Chloride | 3 | 2021 | 38 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 1174 | 0.230 |
Why?
|
| Phenotype | 4 | 2021 | 947 | 0.220 |
Why?
|
| Adenine | 3 | 2017 | 46 | 0.220 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 4848 | 0.210 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2017 | 195 | 0.210 |
Why?
|
| Vasoconstriction | 2 | 2015 | 81 | 0.200 |
Why?
|
| Smad Proteins | 2 | 2014 | 25 | 0.200 |
Why?
|
| Ventricular Remodeling | 3 | 2014 | 318 | 0.200 |
Why?
|
| Biomarkers | 3 | 2019 | 1593 | 0.190 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2020 | 277 | 0.190 |
Why?
|
| Protein Phosphatase 1 | 3 | 2007 | 36 | 0.190 |
Why?
|
| Transforming Growth Factors | 1 | 2021 | 12 | 0.190 |
Why?
|
| Connective Tissue | 1 | 2021 | 61 | 0.190 |
Why?
|
| Karyotype | 2 | 2017 | 7 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 536 | 0.180 |
Why?
|
| Isoenzymes | 3 | 2007 | 308 | 0.180 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2011 | 144 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 4 | 2012 | 615 | 0.170 |
Why?
|
| Adult | 11 | 2019 | 21403 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2019 | 10 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 349 | 0.160 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2019 | 102 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 170 | 0.160 |
Why?
|
| Gene Expression Profiling | 3 | 2010 | 498 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2015 | 15 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2017 | 7029 | 0.150 |
Why?
|
| Vincristine | 1 | 2017 | 44 | 0.150 |
Why?
|
| Etoposide | 1 | 2017 | 64 | 0.150 |
Why?
|
| Mice, Transgenic | 5 | 2017 | 1033 | 0.150 |
Why?
|
| Prednisone | 1 | 2017 | 104 | 0.150 |
Why?
|
| Adventitia | 1 | 2017 | 2 | 0.150 |
Why?
|
| Rituximab | 1 | 2017 | 61 | 0.150 |
Why?
|
| Macrophages | 2 | 2018 | 647 | 0.150 |
Why?
|
| Arterial Pressure | 1 | 2017 | 47 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 129 | 0.150 |
Why?
|
| Blotting, Western | 4 | 2015 | 954 | 0.150 |
Why?
|
| Pancreatic Elastase | 1 | 2017 | 33 | 0.150 |
Why?
|
| Swine, Miniature | 1 | 2017 | 45 | 0.150 |
Why?
|
| Osteonectin | 1 | 2018 | 69 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Cathepsin L | 1 | 2016 | 10 | 0.140 |
Why?
|
| Cathepsin K | 1 | 2016 | 16 | 0.140 |
Why?
|
| Intracellular Space | 1 | 2016 | 42 | 0.140 |
Why?
|
| Aortic Aneurysm | 2 | 2007 | 77 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2017 | 411 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 508 | 0.140 |
Why?
|
| Cardiac Catheterization | 1 | 2019 | 419 | 0.140 |
Why?
|
| Aortic Diseases | 2 | 2015 | 113 | 0.140 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 21 | 0.140 |
Why?
|
| Ventricular Function, Left | 3 | 2020 | 481 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 567 | 0.140 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 232 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2017 | 231 | 0.140 |
Why?
|
| Risk Factors | 5 | 2015 | 5731 | 0.140 |
Why?
|
| Elastic Tissue | 2 | 2017 | 28 | 0.130 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2016 | 59 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 64 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2010 | 682 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2017 | 330 | 0.130 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 337 | 0.130 |
Why?
|
| RNA | 2 | 2014 | 171 | 0.130 |
Why?
|
| Drug Design | 1 | 2016 | 107 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1753 | 0.130 |
Why?
|
| Sequence Deletion | 1 | 2015 | 89 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.130 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 31 | 0.120 |
Why?
|
| Vasodilation | 1 | 2015 | 85 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 118 | 0.120 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2017 | 317 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 116 | 0.120 |
Why?
|
| Cardiomegaly | 1 | 2015 | 213 | 0.120 |
Why?
|
| Enzyme Induction | 2 | 2012 | 119 | 0.120 |
Why?
|
| Arteriovenous Fistula | 1 | 2014 | 25 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2013 | 786 | 0.120 |
Why?
|
| Pulmonary Veins | 1 | 2014 | 56 | 0.110 |
Why?
|
| Base Sequence | 1 | 2015 | 1015 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 46 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 213 | 0.110 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 95 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 597 | 0.110 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 104 | 0.110 |
Why?
|
| Ventricular Pressure | 1 | 2014 | 82 | 0.110 |
Why?
|
| Disease Susceptibility | 2 | 2011 | 179 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 32 | 0.110 |
Why?
|
| Elastin | 2 | 2015 | 116 | 0.110 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 32 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2017 | 718 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 140 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 189 | 0.110 |
Why?
|
| Fibrillins | 2 | 2010 | 24 | 0.110 |
Why?
|
| Fontan Procedure | 1 | 2014 | 129 | 0.100 |
Why?
|
| Cell Line | 1 | 2016 | 1752 | 0.100 |
Why?
|
| Ceramides | 2 | 2007 | 578 | 0.100 |
Why?
|
| Gene Targeting | 1 | 2012 | 58 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2011 | 186 | 0.100 |
Why?
|
| Kinetics | 2 | 2005 | 1047 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 168 | 0.100 |
Why?
|
| Appendectomy | 1 | 2012 | 47 | 0.100 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2012 | 84 | 0.100 |
Why?
|
| Escherichia coli | 2 | 2005 | 368 | 0.100 |
Why?
|
| Cholecystectomy | 1 | 2012 | 79 | 0.100 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 74 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2014 | 276 | 0.100 |
Why?
|
| Logistic Models | 2 | 2013 | 1420 | 0.100 |
Why?
|
| Space Flight | 1 | 2012 | 40 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2012 | 115 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 172 | 0.100 |
Why?
|
| Linear Models | 1 | 2013 | 521 | 0.100 |
Why?
|
| Organ Size | 1 | 2011 | 242 | 0.100 |
Why?
|
| Fibrosis | 3 | 2020 | 371 | 0.090 |
Why?
|
| Microbubbles | 1 | 2010 | 8 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2010 | 20 | 0.090 |
Why?
|
| Genes, Reporter | 2 | 2009 | 191 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2010 | 138 | 0.090 |
Why?
|
| Mitral Valve Prolapse | 1 | 2010 | 40 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 86 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1140 | 0.080 |
Why?
|
| Phospholipase C gamma | 2 | 2015 | 13 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2009 | 167 | 0.080 |
Why?
|
| Flavonoids | 1 | 2009 | 109 | 0.080 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 1447 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1465 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 911 | 0.080 |
Why?
|
| Endothelin-1 | 1 | 2010 | 122 | 0.080 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2008 | 4 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1553 | 0.080 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2008 | 13 | 0.080 |
Why?
|
| Peptide Hydrolases | 1 | 2008 | 82 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2017 | 7277 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2077 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2010 | 453 | 0.080 |
Why?
|
| Stress, Mechanical | 3 | 2017 | 208 | 0.080 |
Why?
|
| Hemodynamics | 3 | 2019 | 705 | 0.080 |
Why?
|
| Threonine | 1 | 2007 | 47 | 0.080 |
Why?
|
| Genotype | 1 | 2010 | 786 | 0.070 |
Why?
|
| Serine | 1 | 2007 | 99 | 0.070 |
Why?
|
| beta Catenin | 1 | 2007 | 73 | 0.070 |
Why?
|
| Microscopy, Video | 1 | 2006 | 27 | 0.070 |
Why?
|
| Stroke Volume | 2 | 2020 | 586 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2021 | 312 | 0.070 |
Why?
|
| beta-Galactosidase | 1 | 2006 | 88 | 0.070 |
Why?
|
| Contrast Media | 1 | 2010 | 595 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2017 | 230 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2005 | 20 | 0.070 |
Why?
|
| Surface Plasmon Resonance | 1 | 2005 | 50 | 0.060 |
Why?
|
| Protein Folding | 1 | 2005 | 82 | 0.060 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.060 |
Why?
|
| Catalytic Domain | 1 | 2005 | 99 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2017 | 144 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 200 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2005 | 223 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2005 | 246 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 322 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 562 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2005 | 235 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2005 | 362 | 0.060 |
Why?
|
| Binding Sites | 1 | 2005 | 631 | 0.060 |
Why?
|
| Lipids | 1 | 2005 | 298 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2019 | 2007 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2005 | 546 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1083 | 0.060 |
Why?
|
| Cell Movement | 2 | 2021 | 630 | 0.060 |
Why?
|
| Protein Binding | 1 | 2005 | 1027 | 0.050 |
Why?
|
| Apoptosis | 1 | 2009 | 1641 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2017 | 1200 | 0.050 |
Why?
|
| Phosphorylase a | 1 | 2002 | 2 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 209 | 0.050 |
Why?
|
| Myelin Basic Protein | 1 | 2002 | 62 | 0.050 |
Why?
|
| Type C Phospholipases | 1 | 2002 | 67 | 0.050 |
Why?
|
| Furin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Lentivirus | 1 | 2021 | 35 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2002 | 234 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2002 | 209 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2021 | 324 | 0.040 |
Why?
|
| Mitochondria | 1 | 2005 | 643 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 742 | 0.040 |
Why?
|
| Echocardiography | 2 | 2014 | 515 | 0.040 |
Why?
|
| Recurrence | 2 | 2015 | 948 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 161 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 848 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 169 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 30 | 0.040 |
Why?
|
| CD11b Antigen | 1 | 2017 | 47 | 0.040 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 27 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 49 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 45 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 86 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 46 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 101 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 72 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2017 | 63 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 1851 | 0.040 |
Why?
|
| Monocytes | 1 | 2017 | 210 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 124 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 87 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2017 | 144 | 0.030 |
Why?
|
| Benzamides | 1 | 2017 | 156 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 442 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 226 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 397 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2017 | 215 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 2015 | 54 | 0.030 |
Why?
|
| Compliance | 1 | 2015 | 26 | 0.030 |
Why?
|
| Ohio | 1 | 2015 | 64 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 266 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 159 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 68 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 282 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 189 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 99 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1330 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2015 | 107 | 0.030 |
Why?
|
| Survival | 1 | 2014 | 22 | 0.030 |
Why?
|
| Heart Bypass, Right | 1 | 2014 | 30 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 563 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 489 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 765 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 507 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1851 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 9 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 514 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 792 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 268 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 159 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2012 | 42 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 81 | 0.030 |
Why?
|
| Microdialysis | 1 | 2012 | 147 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 126 | 0.030 |
Why?
|
| Cholecystitis | 1 | 2012 | 12 | 0.030 |
Why?
|
| Astronauts | 1 | 2012 | 20 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2012 | 48 | 0.020 |
Why?
|
| Appendicitis | 1 | 2012 | 55 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 173 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 102 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2358 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 383 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 782 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2009 | 12 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1864 | 0.020 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2009 | 2 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2009 | 29 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 41 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2009 | 74 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2014 | 738 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 144 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2009 | 80 | 0.020 |
Why?
|
| Lac Operon | 1 | 2009 | 54 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2009 | 150 | 0.020 |
Why?
|
| Rats | 2 | 2009 | 5300 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 509 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1603 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2007 | 169 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 36 | 0.020 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2006 | 11 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2014 | 1615 | 0.020 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2007 | 183 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 434 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2005 | 75 | 0.020 |
Why?
|
| Permeability | 1 | 2005 | 131 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 351 | 0.020 |
Why?
|
| Child | 1 | 2014 | 6405 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2009 | 3705 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1118 | 0.010 |
Why?
|